Filling an Unmet Medical Need in the Veteran Population: First-Line Treatment of Metastatic NSCLC in Those Without Actionable Molecular Subtypes
RELEASE DATE: October 07, 2022
EXPIRATION DATE: October 07, 2023
This program will discuss tumorigenesis in advanced non-small cell lung cancer (NSCLC) and the mechanism of actions of checkpoint inhibitors, the latest clinical data describing the efficacy and safety of first-line use of PD-1 inhibitor therapy, alone and in combination, and the use of immunotherapy in the first-line treatment of NSCLC with no actionable mutations.
